U.S. FDA Grants Magenta Company MGTA-456 Advanced Therapy For Multiple Genetic Metabolic Disorders
-
Last Update: 2020-06-08
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
The U.SFood andDrug(http://Administration (
FDA(http://) has granted the one-time cell therapy MGTA-456 advanced therapeutic (RMAT) for the treatment of multiple inherited metabolic disorders, magenta
(http:// announcedAbout MGTA-456
MGTA-456 is a one-time cell therapy designed to provide the best number of
healthy(http://stem cells for patients who cannot find the right matching donor by amplifying the number of stem cells contained in cord bloodMGTA-456 aims to stop the progression of hereditary metabolic disorders by providing high-dose stem cells that can regenerate in patients and match a good new immune system Magenta is developing MGTA-456 as a treatment for a variety of diseases The company is conducting a Phase II study to evaluate MGTA-456 for treatment of patients with Hurler syndrome, cerebral adrenal leprosy (cALD), isosophilia white matter malnutrition (MLD), or globular leprosy (GLD) at a age older than 6 months
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
